All In MedTech

Device Trial Radar · NCT03635996

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

169

Actual

Start

Dec 10, 2018

Primary completion

Nov 13, 2020

Study completion Nov 13, 2020

Sponsor

Lead sponsor
Milestone Pharmaceuticals Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medpace, Inc.
First posted
Aug 17, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS) 70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular Tachycardia in an outpatient setting (i.e., without medical supervision).

Conditions

  • Paroxysmal Supraventricular Tachycardia

Interventions

  • Etripamil NS 70 mgDrug

    All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug.

  • Aptar Pharma Nasal Spray Bidose SystemDevice

    Patients will self-administer the study drug using the Aptar Pharma Nasal Spray Bidose System. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Conversion of an Episode of PSVT to Sinus Rhythm (SR) After Study Drug Administration.Time frame: 18 months

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Arrhythmia Research Center

    Phoenix, Arizona

  • Arkansas Cardiology

    Little Rock, Arkansas

  • Los Alamitos Cardiovascular

    Los Alamitos, California

31 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.